TABLE 5

Lymphoscintigraphy and SLNB of 2,217 Breast Cancer Patients

		Lymphoscintigraphy		Intraoperative SLN detection		SLN pathology
Characteristic	No. of patients	SLNs ( ± s)	Significance	SLNs ( ± s)	Significance	Patients with metastatic SLNS	Significance
Total	2,217	1.76 ± 1.08		2.85 ± 1.86
Sex			P = 0.377		P = 0.613		P = 0.411
Female	2,215	1.76 ± 1.08		2.50 ± 0.71		560
Male	2	2.50 ± 0.71		2.85 ± 1.87		0
Age			P = 0.000		P = 0.002		P = 0.355
≤50	1,182	1.85 ± 1.13		2.96 ± 1.89		308
50	1,035	1.65 ± 1.00		2.72 ± 1.83		252
Left or right cancer			P = 0.651		P = 0.719		P = 0.371
Bilateral	4	2 ± 0.82		3.00 ± 1.16		2
Left	1,140	1.74 ± 1.02		2.82 ± 1.84		279
Right	1,073	1.78 ± 1.13		2.88 ± 1.89		279
Imaging time			P = 0.275		P = 0.897		P = 0.834
2–4 h after injection	922	1.73 ± 1.04		2.85 ± 1.80		235
16–18 h after injection	1,295	1.78 ± 1.10		2.84 ± 1.91		325
Primary tumor site			P = 0.080		P = 0.316		P = 0.166
Upper inner quadrant	302	1.85 ± 0.98		2.66 ± 1.70		66
Lower inner quadrant	254	1.67 ± 0.89		2.83 ± 1.90		54
Upper outer quadrant	882	1.79 ± 1.19		2.89 ± 1.94		243
Lower outer quadrant	438	1.75 ± 1.13		2.94 ± 1.76		110
Central portion	341	1.65 ± 0.89		2.81 ± 1.90		87
Histopathologic subtype			P = 0.178		P = 0.398		P = 0.000
Ductal	1,821	1.74 ± 1.06		2.83 ± 1.84		484
Lobular	179	1.90 ± 1.22		2.85 ± 1.85		49
Other	217	1.76 ± 1.09		3.01 ± 2.07		27
Clinical T stage			P = 0.098		P = 0.191		P = 0.002
Tis	58	1.90 ± 1.07		3.10 ± 2.26		4
T1	1,179	1.73 ± 1.05		2.79 ± 1.84		294
T2	907	1.77 ± 1.09		2.88 ± 1.85		249
T3	73	2.01 ± 1.23		3.16 ± 2.10		13
ER/PR/HER2			P = 0.311		P = 0.973		P = 0.000
+/+/+	634	1.78 ± 1.12		2.81 ± 1.86		187
−/−/+	329	1.83 ± 1.04		2.87 ± 1.56		68
+/−/− or −/+/− or +/+/−	902	1.70 ± 1.04		2.85 ± 1.95		243
+/−/+ or −/+/+	150	1.86 ± 1.09		2.86 ± 1.89		31
−/−/−	202	1.79 ± 1.22		2.92 ± 1.93		31